In the OPTIC trial, which assessed ponatinib starting doses of 45, 30, and 15 mg QD, 51.6%, 35.5%%, and 25.3%, respectively, of patients with T315I-mutated CML-CP achieved BCR::ABL1 on the International Scale (IS) ≤1% by 12 months (predictive of long-term survival) [1, 16, 19, 20]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.